Reference
- Baur JA, Sinclair DA. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506
- Dong W, Han B, Feng Y, et al. (2010). Pharmacokinetics and biodegradation mechanisms of a versatile carboxymethyl derivative of chitosan in rats: in vivo and in vitro evaluation. Biomacromolecules 11:1527–33
- Elzoghby AO, Samy WM, Elgindy NA. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Rel 157:168–82
- Fu D, Han B, Dong W, et al. (2011). Effects of carboxymethyl chitosan on the blood system of rats. Biochem Biophys Res Commun 408:110–14
- Horan RL, Antle K, Collette AL, et al. (2005). In vitro degradation of silk fibroin. Biomaterials 26:3385–93
- Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–81
- Meyer AS, Yi O-S, Pearson DA, et al. (1997). Inhibition of human low-density lipoprotein oxidation in relation to composition of phenolic antioxidants in grapes (Vitis vinifera). J Agric Food Chem 45:1638–43
- Pace-Asciak CR, Hahn S, Diamandis EP, et al. (1995). The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 235:207–19
- Panagi Z, Beletsi A, Evangelatos G, et al. (2001). Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 221:143–52
- Tahara K, Miyazaki Y, Kawashima Y, et al. (2011). Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm 77:84–8
- Takeuchi H, Yamamoto H, Kawashima Y. (2001). Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47:39–54
- Wang ZY, Song J, Zhang DS. (2009). Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol 15:2995–3002
- Watnasirichaikul S, Rades T, Tucker IG, Davies NM. (2002). Effects of formulation variables on characteristics of poly (ethylcyanoacrylate) nanocapsules prepared from w/o microemulsions. Int J Pharm 235:237–46
- Wenzel E, Somoza V. (2005). Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49:472–81
- Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72
- Wu SL, Sun ZJ, Yu L, et al. (2004). Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol 10:3048–52
- Xiong S, Yu B, Wu J, et al. (2011). Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed Pharmacother 65:2–8